Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline

Li, Bing; Yan, Genquan; Wang, Cuicui; Shen, Chengde; Zhang, Wen; Wang, Wei

doi:10.1016/j.jgar.2021.04.006

Cited by 23 publications

(18 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tetracyclines and tigecycline have concentration-dependent killing, and the AUC/MIC parameter predicts their efficacy. In particular, the AUC/MIC target values for tigecycline ranged between ≥1 (for VAP and bone infections) up to ≥18 (for complicated skin and skin-structures infections) [ 119 ].…”

Section: Resultsmentioning

confidence: 99%

Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part II

et al. 2022

View full text Add to dashboard Cite

In patients that are admitted to intensive care units (ICUs), the clinical outcome of severe infections depends on several factors, as well as the early administration of chemotherapies and comorbidities. Antimicrobials may be used in off-label regimens to maximize the probability of therapeutic concentrations within infected tissues and to prevent the selection of resistant clones. Interestingly, the literature clearly shows that the rate of tissue penetration is variable among antibacterial drugs, and the correlation between plasma and tissue concentrations may be inconstant. The present review harvests data about tissue penetration of antibacterial drugs in ICU patients, limiting the search to those drugs that mainly act as protein synthesis inhibitors and disrupting DNA structure and function. As expected, fluoroquinolones, macrolides, linezolid, and tigecycline have an excellent diffusion into epithelial lining fluid. That high penetration is fundamental for the therapy of ventilator and healthcare-associated pneumonia. Some drugs also display a high penetration rate within cerebrospinal fluid, while other agents diffuse into the skin and soft tissues. Further studies are needed to improve our knowledge about drug tissue penetration, especially in the presence of factors that may affect drug pharmacokinetics.

show abstract

Section: Resultsmentioning

confidence: 99%

Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part II

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previously published studies focused on concentration parameters as a predictor of efficacy (Leng et al, 2021;Xie et al, 2017). Only a safety analysis reported 289 patients with TGC treatment had an incidence of nausea/vomiting of 40.4%, when AUC 0-24 values above the threshold value of 6.87 mg•h/L (Rubino et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study

Yang

Jin²,

Luo³

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…Owing to the very limited therapeutic options, polymyxins and Original Article Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria tigecycline are often prescribed as last-resort therapies. However, there are limitations to these therapies, such as the high nephrotoxicity of polymyxins and unsatisfactory pharmacokinetics of tigecycline (1,2). Furthermore, there is resistance to these therapies following their increased clinical application (3,4).…”

Section: Introductionmentioning

confidence: 99%

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria

Wang¹,

Li²,

Zhao

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Cefiderocol is a promising antimicrobial agent against carbapenem-resistant, Gram-negative bacteria, but susceptibility data from the Chinese mainland are lacking. The aim of the present study was to test the susceptibility of cefiderocol against carbapenem-resistant, Gram-negative bacteria collected from Beijing, China. Methods: Carbapenem-resistant Klebsiella pneumoniae (CR-KP; n=105), carbapenem-resistant Acinetobacter baumannii (CR-AB; n=126), carbapenem-resistant Pseudomonas aeruginosa (CR-PA; n=74), and Stenotrophomonas maltophilia (SM; n=72) isolates were collected from inpatients at 4 tertiary hospitals in Beijing, China. Minimum inhibitory concentrations (MICs) for cefiderocol were determined using irondepleted cation-adjusted Mueller Hinton broth (CAMHB), and for comparators using CAMHB, according to the recommended Clinical and Laboratory Standards Institute (CLSI) methodology. Carbapenemase and other β-lactamase gene profiles were determined using polymerase chain reaction (PCR).Results: Cefiderocol inhibited 100% of CR-KP and CR-PA, and 98.6% of the SM isolates at the susceptibility breakpoint concentration of 4 mg/L. However, the susceptibility rate for cefiderocol against CR-AB was only 62.7%, with MIC 90 values as high as 128 mg/L. Nearly all the cefiderocol-susceptible CR-AB isolates were found to be positive for bla OXA-23 and bla TEM , whereas all the cefiderocol-resistant CR-AB isolates were found to be positive for the bla PER genes, in addition to bla OXA-23 and bla TEM .Conclusions: Cefiderocol showed potent in vitro activity against CR-KP, CR-PA, and SM isolates collected from Beijing, China. However, the resistance rate for cefiderocol against CR-AB was higher than that reported by other research centers, and the presence of bla PER might contribute to resistance in nonsusceptible CR-AB isolates.

show abstract

Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline

Cited by 23 publications

References 74 publications

Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part II

Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part II

Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria

Contact Info

Product

Resources

About